Morphine PRN

ApprovedSmall molecule

IIndiana University

Morphine PRN is one of 9 small molecule programs targeting Neonatal Abstinence Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neonatal Abstinence SyndromeActive, not recruiting

Neonatal Abstinence SyndromeApproved

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Neonatal Abstinence Syndrome

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

5 2

Dolophine

HHikma Pharmaceuticals LLC

Approved

5 3

Catapres

Boehringer Ingelheim

Approved

4 4

Suboxone

IIndivior Inc.

Phase 3

4 5

Luminal

BBiomed Industries, Inc.

Phase 3

3 6

MS Contin

Merck & Co.

Phase 2

2 7

Zofran

Novartis

Phase 2

1 8

Morphine PRN

IIndiana University

Approved

1 9

Clonidine HCL

WWake Forest University Health Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neonatal Abstinence Syndrome1 trial

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

Completed·IIndiana University·Phase 4·NCT04298853·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Morphine PRN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Morphine PRN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Morphine PRN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IIndiana University

Morphine PRN

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neonatal Abstinence Syndrome1 trial

References

Drug Info

Quick Facts

Related News